Drug Profile
Sipuleucel-T - Dendreon Corporation
Alternative Names: APC-8015; APC8015F; Autologous PAP-loaded dendritic cell vaccine - Dendreon; Prostate cancer vaccine (APC-8015) - Dendreon; Prostate-cancer-vaccine-APC-8015-Dendreon; ProvengeLatest Information Update: 22 Nov 2023
Price :
$50
*
At a glance
- Originator Dendreon Corporation
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies; T lymphocyte cell therapies; Tissue extracts
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Prostate cancer
Most Recent Events
- 22 Nov 2023 Dendreon plans the phase III ProvONE trial in Prostate cancer (Metastatic disease) (IV) in November 2023 (NCT06134232)
- 31 Dec 2020 University of Hawaii, Genentech and Dendreon completed the phase Ib trial for Prostate cancer (Hormone refractory, Metastatic disease) in USA (IV) (NCT03024216)
- 12 Mar 2020 Efficacy data from a subgroup analysis of the phase IV PROCEED trial in Prostate cancer released by Dendreon Corporation